Bone Histomorphometry - Osteogenesis Imperfecta - page 217

[8] Paritt AM. Bone-forming cells in clinical conditions Hall BK,
editor. Bone, volume 1: the osteoblast and osteocyte. Caldwell,
New Jersey: Telford Press; 1990. p. 351-429.
[9] Allen MR, Burr DB. Bisphosphonate effects on bone turn-
over, microdamage, and mechanical properties: what we
think we know and what we know that we don't know. Bone
2011;49:56-65.

bone disease with a mineralization defect. J Bone Miner Res
2002;17:30-8.

[28] Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B,

et al. Mutations in SERPINF1 cause osteogenesis imperfecta
type VI. J Bone Miner Res 2011;26:2798-803.

[29] Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M,

Vincenzi M, et al. Lack of expression of SERPINF1, the gene cod-
ing for pigment epithelium-derived factor, causes progressively
deforming osteogenesis imperfecta with normal type I collagen.
J Bone Miner Res 2012;27:723-8.

[10] Frost HM. Skeletal structural adaptations to mechanical usage

(SATMU): 1. Redeining Wolff's law: the bone modeling prob-
lem. Anat Rec 1990;226:403-13.

[11] Rauch F, Travers R, Paritt AM, Glorieux FH. Static and dynamic

bone histomorphometry in children with osteogenesis imper-
fecta. Bone 2000;26:581-9.

[30] Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al.

Exome sequencing identiies truncating mutations in human
SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am
J Hum Genet 2011;88:362-71. [12] Paritt AM, Travers R, Rauch F, Glorieux FH. Structural and

cellular changes during bone growth in healthy children. Bone
2000;27:487-94.

[31] Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone

M, et al. CRTAP is required for prolyl 3-hydroxylation and muta-
tions cause recessive osteogenesis imperfecta. Cell 2006;127:
291-304.

[13] Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B,

Abrahamsen B, et al. Bone geometry, density, and microarchi-
tecture in the distal radius and tibia in adults with osteogene-
sis imperfecta type I assessed by high-resolution pQCT. J Bone
Miner Res 2012;27:1405-12.

[32] Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L,

et al. Osteogenesis imperfecta type VII: an autosomal recessive
form of brittle bone disease. Bone 2002;31:12-18.

[14] Baron R, Gertner JM, Lang R, Vignery A. Increased bone turn-

over with decreased bone formation by osteoblasts in children
with osteogenesis imperfecta tarda. Pediatr Res 1983;17:204-7.

[33] Venturi G, Monti E, Dalle Carbonare L, Corradi M, Gandini A,

Valenti MT, et al. A novel splicing mutation in FKBP10 causing
osteogenesis imperfecta with a possible mineralization defect.
Bone 2012;50:343-9. [15] Davis MS, Kovacic BL, Marini JC, Shih AJ, Kozloff KM.

Increased susceptibility to microdamage in Brtl/+ mouse model
for osteogenesis imperfecta. Bone 2012;50:784-91.

[34] Lindahl K, Barnes AM, Fratzl-Zelman N, Whyte MP, Hefferan TE,

Makareeva E, et al. COL1 C-propeptide cleavage site mutations
cause high bone mass osteogenesis imperfecta. Hum Mutat
2011;32:598-609.

[16] Robling AG, Turner CH. Mechanical signaling for bone modeling

and remodeling. Crit Rev Eukaryot Gene Expr 2009;19:319-38.

[17] McCarthy EF, Earnest K, Rossiter K, Shapiro J. Bone histomor-

phometry in adults with type IA osteogenesis imperfecta. Clin
Orthop 1997;336:254-62.

[35] Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intrave-

nous pamidronate on the bone tissue of children and adolescents
with osteogenesis imperfecta. J Clin Invest 2002;110:1293-9.

[18] Ste-Marie LG, Charhon SA, Edouard C, Chapuy MC, Meunier PJ.

Iliac bone histomorphometry in adults and children with osteo-
genesis imperfecta. J Clin Pathol 1984;37:1081-9.

[36] Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intrave-

nous pamidronate treatment in infants with osteogenesis imper-
fecta: clinical and histomorphometric outcome. J Bone Miner
Res 2005;20:1235-43. [19] Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M.

Vitamin D deiciency in children and its management: review
of current knowledge and recommendations. Pediatrics 2008;
122:398-417.

[37] Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH. The effect

of cyclical intravenous pamidronate in children and adolescents
with osteogenesis imperfecta Type V. Bone 2006;38:13-20.

[20] Edouard T, Glorieux FH, Rauch F. Relationship between vitamin

D status and bone mineralization, mass, and metabolism in chil-
dren with osteogenesis imperfecta: histomorphometric study.
J Bone Miner Res 2011;26:2245-51.

[38] Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imper-

fecta type VI in childhood and adolescence: effects of cyclical
intravenous pamidronate treatment. Bone 2007;40:638-44.

[39] Cheung MS, Glorieux FH, Rauch F. Intravenous pamidronate in

osteogenesis imperfecta type VII. Calcif Tissue Int 2009;84:203-9. [21] Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD,

Milgrom S, et al. Consortium for osteogenesis imperfecta muta-
tions in the helical domain of type I collagen: regions rich in
lethal mutations align with collagen binding sites for integrins
and proteoglycans. Hum Mutat 2007;28:209-21.

[40] Rauch F, Travers R, Glorieux FH. Pamidronate in children with

osteogenesis imperfecta: histomorphometric effects of long-term
therapy. J Clin Endocrinol Metab 2006;91:511-6.

[41] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate

in the treatment of mild pediatric osteogenesis imperfecta:
a randomized placebo-controlled study. J Bone Miner Res
2009;24:1282-9.

[22] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives

on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540-57.

[23] Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between

genotype and skeletal phenotype in children and adolescents
with osteogenesis imperfecta. J Bone Miner Res 2010;25:1367-74.

[42] Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R,

Fedarko N, et al. The effect of intravenous pamidronate on bone
mineral density, bone histomorphometry, and parameters of bone
turnover in adults with type IA osteogenesis imperfecta. Calcif
Tissue Int 2003;72:103-12.

[24] Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P,

et al. Type V osteogenesis imperfecta: a new form of brittle bone
disease. J Bone Miner Res 2000;15:1650-8.

[25] Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single

recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis
imperfecta type V. Am J Hum Genet 2012;91:343-8.

[43] Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphy-

seal lines in a child treated with pamidronate: histomorphomet-
ric analysis. J Bone Miner Res 2004;19:1191-3.

[26] Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J,

et al. A mutation in the 5′-UTR of IFITM5 creates an in-frame start
codon and causes autosomal-dominant osteogenesis imperfecta
type V with hyperplastic callus. Am J Hum Genet 2012;91:349-57.

[44] Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S.

Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;
349:457-63.

[45] Cheung MS, Glorieux FH, Rauch F. Large osteoclasts in pediat-

ric osteogenesis imperfecta patients receiving intravenous pami-
dronate. J Bone Miner Res 2009;24:669-74.

[27] Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ,

Travers R. Osteogenesis imperfecta type VI: a form of brittle